Gabapentin Tablet
Product Images NDC 76420-836

This text is a list of different packaging and details related to Gabapentin tablets in different strengths (600 mg and 800 mg) and quantities (30, 60, 90, 100, and 500). The text includes NDC numbers, lot numbers, manufactured information for Camber Pharmaceuticals, and drug status information. It also mentions "Enovachem" as the brand or distributor of the tablets. *

This text provides a list of symptoms that may be associated with a medical condition. The symptoms include lack of coordination, viral infection, difficulty with speaking, tremor, swelling of legs and feet, feeling tired, fever, feeling drowsy, nausea and vomiting, jerky movements, double vision, and unusual eye movements. These symptoms suggest a potential neurological or viral illness and highlight the importance of seeking medical attention for proper diagnosis and treatment.*

This is a dosage table for Gabapentin based on renal function. The table provides guidance on the total daily dose of Gabapentin based on different ranges of creatinine clearance. It includes dosage regimens for patients with varying levels of renal function, including those on hemodialysis. The table specifies dosing recommendations for different creatinine clearance levels and outlines supplemental post-hemodialysis doses. The abbreviations used in the table include TID (Three times a day), BID (Two times a day), and QD (Single daily dose). It also advises on adjusting the dose for patients with creatinine clearance below 15 mL/min.*

This information includes a table showing the risk by indication for antiepileptic drugs in a pooled analysis. The table compares placebo patients with drug patients in terms of events per 1,000 patients. The data presents relative risk and risk difference, showcasing the incident of events in additional drug patients compared to placebo patients. The table provides valuable insights for evaluating the risks associated with antiepileptic drugs for different indications.*

This is a table listing the adverse reactions reported in pooled placebo-controlled trials for Postherpetic Neuralgia for the medication Gabapentin compared to Placebo. The table provides the percentage of patients experiencing various adverse reactions categorized by different body systems such as Body as a Whole, Digestive System, Metabolic and Nut, Nervous System, Respiratory System, and Special Senses. Adverse reactions included asthenia, infection, accidental injury, diarrhea, dry mouth, constipation, nausea, vomiting, peripheral edema, weight gain, hyperglycemia, dizziness, somnolence, ataxia, abnormal thinking, abnormal gait, incoordination, pharyngitis, amblyopia, conjunctivitis, diplopia, and otitis media with reported blurred vision.*

This is a description of adverse reactions observed in pooled placebo-controlled add-on trials in epilepsy patients over 12 years of age involving Gabapentin®. The table includes percentages of various adverse reactions experienced by patients such as fatigue, back pain, somnolence, dizziness, nystagmus, tremor, dysarthria, depression, dyspepsia, dry mouth, constipation, dental abnormalities, pharyngitis, diplopia, and others. Amblyopia is noted with a description of blurred vision. These findings can be valuable for healthcare professionals in assessing and managing potential side effects of Gabapentin® treatment in epilepsy patients.*

This is a description of adverse reactions reported in a placebo-controlled add-on trial in pediatric epilepsy patients aged 3 to 12 years. The table includes data comparing the incidence of adverse reactions between Gabapentin and Placebo, with categories like Nausea and/or Vomiting, Emotional Lability, and Respiratory Infection. Reference to "Phos b" rooml mtepilepii drag ey" seems to be unclear or potentially an error.*

This is a table showing controlled studies on postherpetic neuralgia (PHN) treatment using gabapentin. The table provides information on the duration of the studies, dosages of gabapentin used, and the number of patients receiving gabapentin versus placebo in each study. In study 1, the duration was 8 weeks with a target dose of 3600 mg/day, and in study 2 the duration was 7 weeks with doses of 1800 and 2400 mg/day. The total number of patients included in the studies was 336 for gabapentin and 221 for placebo. Gabapentin was given in three divided doses throughout the day.*

This text provides a formula for calculating the estimated glomerular filtration rate (eGFR) based on age, weight, and serum creatinine levels. The formula suggests using the result of "(140 - age) * weight * 0.65 (for female patients) / 72 * serum creatinine" for this calculation. This formula can be useful in assessing kidney function in medical settings.*

This is a figure depicting the weekly mean pain scores observed in the ITT population for Study 1. The pain scores are shown for different weeks along with a baseline score. It also indicates the use of Gabapentin at 3500 iy.*

This text provides information about the proportion of responders in controlled postherpetic neuralgia (PHN) studies. The data includes the percentage reduction in pain scores at the endpoint for patients receiving different treatments. Study 1 and Study 2 are mentioned, along with the specific medications used (PBO, GBP 1800, GBP 2400).*